UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of ~~earliest~~ earliest event reported): ~~May~~August 168, 2024

Intorio, Corp.

(Exact name of registrant as specified in its charter)

Nevada

(State or other jurisdiction
of incorporation)

333-255055
(Commission
File Number)

98-1578603
(IRS Employer
Identification No.)

17875 Von Karman Avenue,

Irvine, California 92614

(Address of Principal Executive Offices)

(323) 909-2866

Registrant’s telephone number, including area code:

______________________________________

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
N/A	N/A	N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 54.01 Changes in ~~Control~~Registrant’s ofCertifying ~~Registrant~~Accountant.

~~Effective May 16, 2024, Gagi Gogolashvili, the previous sole officer and director and majority shareholder of Intorio, Corp.~~ (~~the “Company”~~a), ~~entered~~Resignation ~~into a stock purchase agreements for the sale~~ of ~~2,000,000~~Independent ~~shares of Common Stock of the Company, representing approximately 89% of the issued and outstanding~~Registered ~~shares~~Public ofAccounting Common Stock of the Company as of such date, to six (6) accredited investors, and as such they are able to unilaterally control the election of our board of directors, all matters upon which shareholder approval is required and, ultimately, the direction of our Company.Firm

~~Upon~~On ~~the resignation of Mr. Gogolashvili from~~August ~~all~~20, ~~executive~~2024, ~~officer~~Victor ~~positions with the Company~~Mokuolu, ~~including~~Certified ~~Chief~~Public ~~Executive Officer and President~~Accountants, ~~and~~resigned as athe ~~member~~independent ofregistered ~~the~~public ~~Board,~~accounting ~~effective May~~firm ~~16,~~of ~~2024~~Intorio, DrCorp.. (the ~~Han-Wen Ou was appointed as Chief Executive Officer, Chief Financial Officer, Secretary and sole Director~~“Company”).

~~Item~~Victor ~~5.02~~Mokuolu ~~Departure~~report on the financial statements from March 8, 2022 through May 2, 2024 the last reports issued by Victor Mokuolu, contained no adverse opinion or disclaimer of ~~Directors~~opinion, and were not qualified or ~~Principal~~modified ~~Officers;~~as ~~Election~~to ofuncertainty, audit ~~Directors;~~scope ~~Appointment~~or ofaccounting ~~Principal~~principle, ~~Officers~~other than an explanatory paragraph as to a going concern.

~~The~~During ~~disclosures~~the ~~set~~the ~~forth~~period infrom ~~Item~~March ~~5.01~~8, ~~above~~2022 to ~~are~~May 2, 2024, (a) there were no disagreements with Victor Mokuolu on any matter of accounting principles or practices, financial statement ~~incorporated~~disclosure byor auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Victor Mokuolu, would have caused them to make reference ~~into~~to ~~this~~the subject matter of the disagreements in its reports on the financial statements for such year and (b) there were no reportable events as defined in Item ~~5.02~~304(a)(1)(v) of Regulation S-K.

~~The~~A ~~business~~copy ~~background descriptions~~ of ~~the~~Victor ~~newly appointed~~Mokuolus ~~officer~~resignation ~~and~~letter ~~director~~ is attached hereto as ~~follows:~~Exhibit 16.1.

~~Han-Wen~~(b) OuNew -Independent ~~Chief~~Registered ~~Executive~~Public ~~Officer and Director~~Accounting Firm

~~Dr.~~On OuAugust ~~has~~8, ~~received~~2024, ~~the~~our ~~following~~board ~~degrees: a Bachelor~~ of ~~Science~~directors ~~(BSc)~~approved ~~from~~the ~~Taipei Medical University, a Master~~ engagement of ~~Functional~~Michael ~~Medicine~~Gillespie ~~(MSc)~~& ~~from~~Associates, ~~University~~PLLC ~~of Western State~~ (~~UWS~~“MG&A”), ~~and~~as athe ~~Doctor~~Company’s ofnew ~~Clinical~~independent ~~Nutrition~~registered ~~(PhD,~~public ~~DCN) from Maryland University of Integrative Health (MUIH)~~accounting firm.

~~Dr.~~During Outhe ~~was~~Company’s ~~formerly~~most arecent ~~Resident~~fiscal atyear ~~Taipei Veterans~~end ~~General~~and ~~Hospital~~any ~~(TVGH),~~subsequent ~~and~~interim anperiod ~~Attending~~preceding ~~Physician~~the engagement of ~~Family~~MG&A, ~~Medicine at Taipei~~neither ~~City~~the ~~Hospital.~~Company Henor isanyone ~~currently~~acting ~~Director~~on ofour ~~The~~behalf, ~~American~~has ~~Academy~~consulted ofwith ~~Anti-Aging~~MG&A ~~Medicine~~regarding either: (~~A4M~~i) the application of ~~Taiwan,~~accounting ~~China~~principles to a specified transaction, ~~and~~either ~~Singapore~~contemplated or proposed, ~~Director~~(ii) the type of ~~Chinese~~audit ~~Functional~~opinion ~~Medicine~~that ~~Association~~might be rendered on the Company’s financial statements, or (~~CFMA~~iii), ~~Director~~any matter that was either the subject of ~~REDOX~~a ~~Integrative~~disagreement ~~Functional Medicine~~between ~~Center~~the Company and ~~Director~~MG&A as described in Item 304(a)(1)(iv) of ~~REDOX~~Regulation ~~Biomedicine~~S-K ~~CO.,~~or ~~LTD~~a reportable event as described in Item 304(a)(1)(v) of Regulation S-K.

Item 89.01 ~~Other~~Financial ~~Events~~Statements and Exhibits.

~~Change~~(d) ~~in Address of Company~~Exhibits.

Effective May 16, 2024, the Company’s location and the location of the Company’s books and records has changed from 24 Alexander Kazbegi Ave, Tbilisi 0177, Georgia, to 17875 Von Karman Avenue, Irvine, California 92614.

	16.1	Letter from Victor Mokuolu, CPA PLLC
	104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	INTORIO, CORP.
Dated: May 28, 2024	By:	/s/ Han-Wen Ou
Dated: August 21, 2024	By:	/s/ Han-Wen Ou
	Name:	Han-Wen Ou
	Title:	CEO

Filing Compare · Redox International Group, Corp.